Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niels Pallisgaard

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
European Journal of Haematology|May 8, 2015
Molecular diagnostics of myeloproliferative neoplasmsStephen E Langabeer, Hajnalka Andrikovics, Julia Asp, et al.
Gut|February 7, 2015
Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgeryThomas Reinert, Lone V Schøler, Rune Thomsen, et al.
Cancer Medicine|June 23, 2018
Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosisStine Ulrik Mikkelsen, Lasse Kjaer, Mads Emil Bjørn, et al.
Blood|November 19, 2005
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosisPeter J Campbell, Martin Griesshammer, Konstanze Döhner, et al.
British Journal of Haematology|June 11, 2021
Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory studyStuart Scott, Ashley Cartwright, Sebastian Francis, et al.
Haematologica|October 15, 2020
Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II studyAnders Lindholm Sørensen, Stine Ulrik Mikkelsen, Trine Alma Knudsen, et al.
Annals of Hematology|December 12, 2018
International external quality assurance of JAK2 V617F quantificationJulia Asp, Vibe Skov, Beatriz Bellosillo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2026
Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C TrialIsmail Gögenur, Tobias F Justesen, Line S Tarpgaard, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
European Journal of Haematology|May 8, 2015
Molecular diagnostics of myeloproliferative neoplasmsStephen E Langabeer, Hajnalka Andrikovics, Julia Asp, et al.
Gut|February 7, 2015
Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgeryThomas Reinert, Lone V Schøler, Rune Thomsen, et al.
Cancer Medicine|June 23, 2018
Safety and efficacy of combination therapy of interferon-α2 and ruxolitinib in polycythemia vera and myelofibrosisStine Ulrik Mikkelsen, Lasse Kjaer, Mads Emil Bjørn, et al.
Blood|November 19, 2005
V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosisPeter J Campbell, Martin Griesshammer, Konstanze Döhner, et al.
British Journal of Haematology|June 11, 2021
Assessment of droplet digital polymerase chain reaction for measuring BCR-ABL1 in chronic myeloid leukaemia in an international interlaboratory studyStuart Scott, Ashley Cartwright, Sebastian Francis, et al.
Haematologica|October 15, 2020
Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II studyAnders Lindholm Sørensen, Stine Ulrik Mikkelsen, Trine Alma Knudsen, et al.
Annals of Hematology|December 12, 2018
International external quality assurance of JAK2 V617F quantificationJulia Asp, Vibe Skov, Beatriz Bellosillo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 5, 2026
Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C TrialIsmail Gögenur, Tobias F Justesen, Line S Tarpgaard, et al.
Pageof 7